Company profile for 4TEEN4 Pharmaceuticals

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

4TEEN4, headquartered in Hennigsdorf, Germany, develops a first-in-class monoclonal antibody, procizumab, targeting circulating dipeptidyl peptidase 3 (cDPP3), a key driver of mortality in shock. cDPP3 enters the bloodstream after tissue injury, disrupting the renin-angiotensin-aldosterone system and causing hemodynamic instability and organ failure. Built on the discovery of this pathway, the company applies expertise in card...
4TEEN4, headquartered in Hennigsdorf, Germany, develops a first-in-class monoclonal antibody, procizumab, targeting circulating dipeptidyl peptidase 3 (cDPP3), a key driver of mortality in shock. cDPP3 enters the bloodstream after tissue injury, disrupting the renin-angiotensin-aldosterone system and causing hemodynamic instability and organ failure. Built on the discovery of this pathway, the company applies expertise in cardiovascular research and drug development to advance a targeted, pathophysiology-driven therapy for critically ill patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
Neuendorfstrasse 15A, 16761 Hennigsdorf
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/13/3187076/0/en/4TEEN4-Extends-Series-C-Financing-Round-to-55-Million-Supporting-Expanded-Clinical-Development-of-Procizumab-in-Cardiogenic-Shock.html

GLOBENEWSWIRE
13 Nov 2025

https://www.globenewswire.com/news-release/2025/07/23/3120062/0/en/4TEEN4-Doses-First-Patient-in-Phase-1b-2a-Trial-of-Procizumab-a-Monoclonal-Antibody-Targeting-the-Biological-Driver-of-Shock.html

GLOBENEWSWIRE
23 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty